A groundbreaking collaboration between Adcendo and Merck & Co. (MSD) is set to redefine the treatment landscape for advanced solid tumors. The two pharmaceutical giants have announced a significant partnership to evaluate Adcendo’s investigational antibody-drug conjugate (ADC), ADCE-T02, in combination with MSD’s renowned anti-PD-1 therapy, Keytruda (pembrolizumab), within a pivotal Phase Ib clinical trial. This alliance signifies a shared commitment to harnessing the synergistic potential of targeted ADC therapy and immunotherapy to achieve improved clinical outcomes for patients battling some of the most challenging cancers.
The agreement will see Adcendo sponsoring the Phase Ib clinical trial, while MSD will provide the supply of pembrolizumab. Crucially, both companies will retain full commercial rights to their respective compounds, whether utilized as standalone treatments or as part of combination regimens. This structure underscores the strategic importance of this collaboration for both organizations, paving the way for potential future commercialization of this promising therapeutic approach.
Unveiling the Therapeutic Arsenal: ADCE-T02 and Keytruda
At the heart of this alliance lies ADCE-T02, Adcendo’s innovative ADC designed to precisely target tissue factor (TF). Tissue factor is a cell surface protein implicated in a myriad of biological processes, including coagulation and inflammation, and is known to be aberrantly overexpressed in a significant proportion of solid tumors. ADCE-T02 leverages this overexpression by employing a targeted delivery mechanism. Its design integrates a potent topoisomerase-1 inhibitor payload, which is released specifically within cancer cells that express tissue factor, thereby minimizing off-target toxicity and maximizing anti-tumor effect.
Complementing ADCE-T02’s targeted cytotoxic action is Keytruda (pembrolizumab), a powerhouse in the field of cancer immunotherapy. Keytruda is a humanized antibody that blocks the interaction between the programmed cell death protein 1 (PD-1) receptor and its ligands (PD-L1 and PD-L2). By inhibiting this crucial immune checkpoint pathway, Keytruda unleashes the patient’s own immune system to recognize and attack cancer cells, which often exploit the PD-1 pathway to evade immune surveillance.
The rationale behind combining these two distinct yet complementary mechanisms of action is compelling. While ADCE-T02 directly attacks tumor cells via targeted drug delivery, Keytruda aims to bolster the body’s immune response against the cancer. The hypothesis is that by reducing the tumor burden with ADCE-T02 and simultaneously enhancing the immune system’s ability to clear remaining cancer cells with Keytruda, a more profound and durable anti-tumor response can be achieved. This dual-pronged attack strategy holds the potential to overcome resistance mechanisms that can limit the efficacy of single-agent therapies.
A Chronology of Hope: The Road to Clinical Evaluation
The announcement of this collaboration marks a significant milestone in Adcendo’s development pipeline and a testament to MSD’s ongoing commitment to advancing oncology research. The Phase Ib clinical trial, slated to begin dosing its first patient in the second half of 2026, will represent a critical step in evaluating the safety and efficacy of this novel combination.
This upcoming trial will build upon existing research and preclinical data supporting the rationale for combining tissue factor-targeting ADCs with PD-1 inhibitors. Adcendo’s lead program, ADCE-T02, is already undergoing evaluation as a monotherapy in the Phase I Tiffany-01 study, also targeting patients with advanced solid tumors. This ongoing monotherapy study will provide valuable insights into the tolerability and pharmacokinetic profile of ADCE-T02, which will inform the design and interpretation of the combination trial.
The Phase Ib study itself will be meticulously designed to assess the tolerability and safety of escalating doses of ADCE-T02 administered alongside a standard dose of pembrolizumab. The primary objectives will be to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the combination, while simultaneously evaluating preliminary efficacy signals. This dose-escalation approach is standard practice in early-phase clinical trials, ensuring patient safety as researchers explore new therapeutic frontiers.
The strategic decision to advance ADCE-T02 into a combination trial with Keytruda highlights Adcendo’s forward-thinking approach to drug development. The company’s pipeline also includes other promising ADC candidates, such as ADCE-D01 targeting uPARAP and ADCE-B05, which is currently in clinical evaluation for squamous cell solid tumors. This broad portfolio demonstrates Adcendo’s dedication to developing targeted therapies across a range of cancer indications.
Furthermore, this collaboration with Adcendo is not an isolated event for MSD in the realm of novel combination strategies. Earlier in the month, MSD announced a similar clinical trial collaboration and supply agreement with Erasca to investigate ERAS-0015 in combination with Keytruda for patients with RAS-mutant solid tumors. These parallel initiatives underscore MSD’s proactive strategy to explore synergistic combinations that can address unmet needs in difficult-to-treat cancers.
Supporting Data and Scientific Rationale
The scientific underpinnings of this collaboration are rooted in a growing body of evidence supporting the role of tissue factor in cancer progression and immune evasion, as well as the transformative impact of immunotherapy.
Tissue Factor’s Multifaceted Role in Cancer:
Tissue factor, beyond its well-established role in hemostasis, has been increasingly recognized for its pro-tumorigenic functions. Its overexpression in various malignancies, including head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and cervical cancer – specific indications mentioned by Adcendo’s CMO – is associated with:
- Tumor Angiogenesis: TF can promote the formation of new blood vessels that supply tumors with nutrients and oxygen, facilitating their growth and metastasis.
- Metastasis: TF signaling can enhance tumor cell invasion and migration, contributing to the spread of cancer to distant sites.
- Immune Suppression: TF can directly influence the tumor microenvironment, suppressing anti-tumor immune responses. It can recruit myeloid-derived suppressor cells (MDSCs) and modulate the activity of other immune cells, creating an immunosuppressive milieu that allows the tumor to evade immune detection.
- Chemotherapy Resistance: In some cases, TF expression has been linked to resistance to conventional chemotherapy agents.
By targeting TF with ADCE-T02, Adcendo aims to disrupt these pro-tumorigenic processes directly. The targeted delivery of a cytotoxic payload ensures that the drug is concentrated at the tumor site, potentially leading to higher efficacy and reduced systemic toxicity compared to conventional chemotherapies.
The Synergy of ADCs and Immunotherapy:
The combination of ADCs and immunotherapies is a rapidly evolving area of oncology research, driven by the potential for synergistic effects. The rationale for combining ADCE-T02 with Keytruda is multifaceted:
- Reducing Tumor Burden: Effective tumor cell killing by ADCE-T02 can lead to the release of tumor-associated antigens (TAAs) and damage-associated molecular patterns (DAMPs). These released components can prime and activate the immune system, making it more receptive to the effects of PD-1 blockade.
- Modulating the Tumor Microenvironment: By eliminating TF-expressing tumor cells, ADCE-T02 may also reduce the immunosuppressive signaling associated with TF in the tumor microenvironment. This could create a more favorable environment for T-cell infiltration and activity, thereby enhancing the efficacy of Keytruda.
- Overcoming Immune Evasion: Cancer cells often employ multiple mechanisms to evade immune detection. Combining a targeted cytotoxic agent with an immune checkpoint inhibitor addresses different aspects of tumor escape, potentially leading to a more comprehensive and durable anti-tumor response.
- Broad Applicability: The expression of tissue factor is prevalent across a wide range of solid tumors, suggesting that this combination approach could have broad applicability in advanced cancer treatment.
Dr. Lone Ottesen, Adcendo’s Chief Medical Officer, articulated this sentiment clearly: "Through this collaboration of potentially complementary mechanisms, we may be able to positively impact clinical outcomes for patients battling cancers where tissue factor is known to be overexpressed such as head and neck squamous cell carcinoma, non-small cell lung cancer and cervical cancer." Her statement underscores the targeted approach and the specific cancer types where this combination is anticipated to have the greatest impact.
Official Responses and Strategic Vision
The strategic alliance between Adcendo and MSD has been met with enthusiasm from leadership within both organizations, highlighting their shared vision for advancing cancer care.
Dr. Lone Ottesen, Chief Medical Officer at Adcendo, expressed her excitement about the partnership: “We are excited to work together with MSD on this new clinical trial combining ADCE-T02, our novel tissue factor-targeting ADC, with pembrolizumab. Through this collaboration of potentially complementary mechanisms, we may be able to positively impact clinical outcomes for patients battling cancers where tissue factor is known to be overexpressed such as head and neck squamous cell carcinoma, non-small cell lung cancer and cervical cancer.” Her statement emphasizes Adcendo’s confidence in the scientific rationale and the potential of ADCE-T02 to address significant unmet needs.
While MSD has not released a specific statement for this particular collaboration as of the provided information, their consistent investment in and pursuit of novel combination therapies, as evidenced by their recent partnership with Erasca, speaks volumes about their strategic priorities. MSD’s commitment to Keytruda extends beyond monotherapy, with a robust clinical development program exploring its combination with a wide array of agents, including chemotherapy, targeted therapies, and other immunotherapies. This proactive approach reflects a deep understanding that the future of cancer treatment lies in personalized, multi-modal strategies.
The agreement’s structure, where both companies retain commercial rights to their respective compounds, suggests a collaborative spirit focused on maximizing the therapeutic potential of the combination. This model can facilitate accelerated development and a more streamlined path to market, should the clinical trials prove successful.
Implications for the Future of Cancer Treatment
The collaboration between Adcendo and MSD carries profound implications for the future of cancer treatment, particularly for patients with advanced solid tumors.
1. Advancing Targeted Therapies and Immunotherapy Integration: This trial represents a significant step forward in the integration of antibody-drug conjugates (ADCs) with immune checkpoint inhibitors. As ADCs mature as a therapeutic modality, their potential to synergize with immunotherapies is becoming increasingly apparent. This partnership will provide crucial clinical data to validate this approach, potentially paving the way for a new class of combination therapies.
2. Addressing Unmet Needs in Difficult-to-Treat Cancers: Cancers like head and neck squamous cell carcinoma, non-small cell lung cancer, and cervical cancer, especially in their advanced stages, often present significant treatment challenges. The over-expression of tissue factor in these malignancies makes them prime candidates for therapies like ADCE-T02. Combining this with the proven efficacy of Keytruda offers a renewed hope for patients who have exhausted or are refractory to existing treatment options.
3. Catalyzing Further Research and Development: The success of this Phase Ib trial could serve as a catalyst for further research into tissue factor-targeting ADCs in combination with various immunotherapies. It may also stimulate the development of novel ADCs targeting other tumor-associated antigens that can synergize with PD-1 blockade.
4. Economic and Strategic Impact: For Adcendo, this collaboration provides access to a world-class partner and a globally recognized therapeutic agent, significantly accelerating its path to potential market entry. For MSD, it reinforces their leadership in oncology and expands their portfolio of innovative combination strategies, potentially securing future revenue streams.
5. Patient-Centric Approach: Ultimately, the most significant implication is for patients. This alliance signifies a commitment to exploring novel treatment paradigms that have the potential to improve survival rates, enhance quality of life, and offer new hope to individuals facing life-threatening cancers. The meticulous design of the trial, focusing on safety, tolerability, and preliminary efficacy, underscores a patient-centric approach to drug development.
In conclusion, the strategic alliance between Adcendo and MSD to evaluate ADCE-T02 in combination with Keytruda is a landmark event in the ongoing battle against cancer. It embodies the spirit of innovation and collaboration that is essential for pushing the boundaries of medical science and delivering transformative treatments to patients worldwide. The coming years will be critical as this promising combination undergoes rigorous clinical evaluation, with the potential to usher in a new era of cancer therapy.
About the Author
